Asiaticoside induction for cell-cycle progression, proliferation and collagen synthesis in human dermal fibroblasts

2004 ◽  
Vol 43 (11) ◽  
pp. 801-807 ◽  
Author(s):  
Luo Lu ◽  
Kang Ying ◽  
Shaoming Wei ◽  
Yong Fang ◽  
Yuliang Liu ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cell Cycle Progression ◽  
Collagen Synthesis ◽  
Dermal Fibroblasts ◽  
Human Dermal Fibroblasts ◽  
Cycle Progression

LncRNA RP11-670E13.6 Regulates Cell Cycle Progression in UVB Damaged Human Dermal Fibroblasts

2018 ◽  
Vol 94 (3) ◽  
pp. 589-597 ◽  
Author(s):  
Mengna Li ◽  
Li Li ◽  
Xiaofeng Zhang ◽  
Yan Yan ◽  
Baoxi Wang
Keyword(s):  
Cell Cycle ◽  
Cell Cycle Progression ◽  
Dermal Fibroblasts ◽  
Human Dermal Fibroblasts ◽  
Cycle Progression

Centrosome Aberrations, Disturbed Mitotic Spindle Formation and G1 Arrest in Normal and Leukemic Cells Treated with the SRC/ABL Inhibitor Dasatinib.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2167-2167
Author(s):  
Alice Fabarius ◽  
Michelle Giehl ◽  
Alwin Kraemer ◽  
Oliver Frank ◽  
Martin C. Mueller ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cell Lines ◽  
Mitotic Spindle ◽  
Cell Cycle Progression ◽  
Dermal Fibroblasts ◽  
G1 Arrest ◽  
Osteosarcoma Cell ◽  
Cycle Progression ◽  
Spindle Formation

Abstract Multitargeted ABL inhibitors have been developed to simultaneously inhibit various pathways associated with proliferation in BCR-ABL+ diseases. Dasatinib (Bristol Myers Squibb) is a potent inhibitor targeting ABL, SRC, and other tyrosine kinases. SRC kinases are required for progression through the initial phase of mitosis. Centrosomes play a fundamental role in mitotic spindle organization, chromosome segregation and genetic stability. We sought to evaluate the activity of dasatinib on proliferation, centrosome status, spindle formation, and cell cycle progression in vitro and in vivo. Normal human dermal fibroblasts (NHDF), Chinese hamster embryonal fibroblasts (CHE), and the human osteosarcoma cell line U2OS were treated with serial concentrations (1nM-10μM) of dasatinib for 3 weeks. Effects of dasatinib were compared with data achieved with the ABL inhibitors imatinib (Novartis, 5–20μM) and nilotinib (Novartis, 0.5–20μM), the specific SRC inhibitor PP2 (Calbiochem-Novabiochem, 0.1–2μM), the ABL/LYN inhibitor INNO-406 (Innovive, 0.1–2μM), and solvent control. Bone marrow and peripheral blood samples from 18 patients (pts, 10 m, 8 f; median age 57 yrs, range 26–75) treated with dasatinib (70mg bid) after imatinib failure for a median of 11 mo (range, 3–16) were investigated. 17 pts had chronic myeloid leukemia (CML) in chronic phase. One patient suffered from a gastrointestinal stromal tumor. For comparison, 3 untreated CML pts and 3 healthy individuals were evaluated. Cell proliferation was determined in liquid culture incubated with serial dilutions of the inhibitor. Centrosome morphology and spindle formation were evaluated after pericentrin and α-tubulin staining, respectively. Cell cycle progression was analyzed by FACS and expression of EG5 by immunofluorescence microscopy. Dasatinib induced a G1 cell cycle arrest in all cell lines tested and in pts associated with a shift to 1n DNA ploidy and absence of EG5 as a marker for G2 phase/mitosis. In vitro, centrosomal aberrations and delay of spindle formation were observed in a dose dependent fashion. In pts, centrosome alterations were found in a median of 17% (range, 10–15) of cells. Disturbed spindle formation was observed in 9/18 pts. In comparison, incubation with imatinib and nilotinib was associated with centrosome aberrations but not with defects of spindle formation and G1 arrest. PP2 induced S-phase arrest; centrosome aberrations were observed at higher dosages (1–2 μM) only, spindle formation was not affected. INNO-406 was associated with both centrosome aberrations and disturbed spindle formation. In pharmacological doses, proliferation of BCR-ABL neg. cell lines was inhibited after dasatinib treatment, but not after incubation with imatinib, nilotinib, PP2, or INNO-406. In conclusion, dasatinib blocks the G1/S transition and thereby inhibits cell growth in normal and neoplastic cells. In addition, it induces both centrosomal and spindle aberrations. Effects of dasatinib are not based on SRC inhibition alone but may be associated with the combination of SRC and ABL inhibition or with non-specific effects on multiple kinases. Therefore, dasatinib should be defined as a cytostatic drug with a strong targeted component resulting in a preferential inhibition of cells harboring a specific target, like BCR-ABL.

E2F4 plays a much more important role than E2F1 in the promotion of cell cycle progression of human intestinal cells

2001 ◽  
Vol 120 (5) ◽  
pp. A501-A502
Author(s):  
C DESCHENES ◽  
A VEZINA ◽  
N RIVARD
Keyword(s):  
Cell Cycle ◽  
Cell Cycle Progression ◽  
Intestinal Cells ◽  
Cycle Progression ◽  
Human Intestinal Cells

The inner plasma membrane protein Plac8 regulates cell cycle progression in pancreatic ductal adenocarcinoma (PDAC)

2015 ◽  
Vol 53 (08) ◽  
Author(s):  
M Buchholz ◽  
B Kaistha ◽  
H Lorenz ◽  
H Schmidt ◽  
N Weber-Lassalle ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Plasma Membrane ◽  
Membrane Protein ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Cell Cycle Progression ◽  
Ductal Adenocarcinoma ◽  
Plasma Membrane Protein ◽  
Cycle Progression

MicroRNA - 497~195 cluster suppresses cell cycle progression by targeting CCND3/CDK4 in acute lymphoblastic leukemia

2020 ◽  
Author(s):  
E Boldrin ◽  
E Gaffo ◽  
JM Boer ◽  
R Claus ◽  
C Plass ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Acute Lymphoblastic Leukemia ◽  
Cell Cycle Progression ◽  
Lymphoblastic Leukemia ◽  
Cycle Progression

Modulation of cell cycle progression by combined rapamycin-octreotide treatment in pituitary tumor cells

2007 ◽  
Vol 115 (08) ◽  
Author(s):  
V Cerovac ◽  
M Reimann ◽  
GK Stalla ◽  
M Theodoropoulou
Keyword(s):  
Cell Cycle ◽  
Tumor Cells ◽  
Pituitary Tumor ◽  
Cell Cycle Progression ◽  
Cycle Progression ◽  
Octreotide Treatment

Cell Cycle Progression

2020 ◽  
Author(s):  
Keyword(s):  
Cell Cycle ◽  
Cell Cycle Progression ◽  
Cycle Progression

1955-P: GLP-1R Activation Attenuates Prostate Cancer Growth via Inhibiting Cell Cycle Progression

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1955-P
Author(s):  
TORU SHIGEOKA ◽  
TAKASHI NOMIYAMA ◽  
TAKAKO KAWANAMI ◽  
YURIKO HAMAGUCHI ◽  
TOMOKO TANAKA ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Cycle ◽  
Cell Cycle Progression ◽  
Cancer Growth ◽  
Cycle Progression
Sign in / Sign up

Export Citation Format

Share Document